Interferon alfacon1 is an inhibitor of SARS-corona virus in cell-based models

Preliminary data examining interferon alfacon1 treatment of SARS-CoV (severe acute respiratory syndrome-corona virus)-infected patients suggests this therapy is well tolerated and of therapeutic benefit. We report herein that interferon alfacon1, has potent in vitro antiviral activity against SARS-C...

Full description

Saved in:
Bibliographic Details
Published in:Antiviral research 2005-06, Vol.66 (2), p.99-102
Main Authors: Paragas, Jason, Blatt, Lawrence M., Hartmann, Chris, Huggins, John W., Endy, Tim P.
Format: Article
Language:English
Subjects:
Alfacon1
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiviral
Antiviral agents
Antiviral Agents - pharmacology
Biological and medical sciences
Cytopathogenic Effect, Viral
Humans
Interferon
Interferon Type I - pharmacokinetics
Interferon Type I - pharmacology
Interferon-alpha
Medical sciences
Microbial Sensitivity Tests
Models, Biological
Pharmacology. Drug treatments
Recombinant Proteins
SARS coronavirus
SARS Virus - drug effects
SARS-corona
Therapy
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Preliminary data examining interferon alfacon1 treatment of SARS-CoV (severe acute respiratory syndrome-corona virus)-infected patients suggests this therapy is well tolerated and of therapeutic benefit. We report herein that interferon alfacon1, has potent in vitro antiviral activity against SARS-CoV. In a cytopathic effect protection (CPE) assay, interferon alfacon1 inhibited the generation of CPE in a dose-dependent manner with an IC 50 of 0.001 μg/ml, a clinically achievable level. Furthermore, interferon alfacon1 also demonstrated significant antiviral activity in yield reduction and plaque reduction assays. The in vitro antiviral activity of interferon alfacon1 against SARS-CoV suggests continued evaluation of interferon alfacon1 as a therapeutic treatment for patients infected with SARS-CoV.
ISSN:0166-3542
1872-9096
DOI:10.1016/j.antiviral.2005.01.002